Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
[Paper-level Aggregated] PMCID: PMC8203843
Evidence Type(s): Oncogenic
Summary: Mutation: R132H | Summary: The R132H variant contributes to tumor development and progression, particularly in the context of glioma, as it is implicated in cancer-related pathways.
Gene→Variant (gene-first): IDH1(3417):R132H
Genes: IDH1(3417)
Variants: R132H
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
[Paper-level Aggregated] PMCID: PMC8203843
Evidence Type(s): Predictive
Summary: Mutation: R132H | Summary: The R132H variant is associated with sensitivity to PARP inhibitors, indicating a correlation with treatment response.
Gene→Variant (gene-first): IDH1(3417):R132H
Genes: IDH1(3417)
Variants: R132H
As described earlier, ATRX and IDH1/2 mutations co-occur frequently in glioma, and we and others have reported that the latter induce HR defects and PARP inhibitor sensitivity. We thus wanted to understand how PARPi sens
[Paragraph-level] PMCID: PMC8203843 Section: RESULTS PassageIndex: 11
Evidence Type(s): Predictive, Oncogenic
Summary: Evidence Type: Predictive | Mutation: R132H | Summary: The IDH1 R132H mutation is associated with sensitivity to PARP inhibitors, indicating a correlation with treatment response. Evidence Type: Oncogenic | Mutation: R132H | Summary: The IDH1 R132H mutation contributes to tumor development and progression, particularly in the context of glioma.
Gene→Variant (gene-first): 3417:R132H
Genes: 3417
Variants: R132H
IDH1 R132H and ATRX KO have similar levels of PARP inhibitor sensitivity.
[Paragraph-level] PMCID: PMC8203843 Section: ABSTRACT PassageIndex: 4
Evidence Type(s): Predictive, Oncogenic
Summary: Evidence Type: Predictive | Mutation: R132H | Summary: The R132H variant is associated with sensitivity to PARP inhibitors, indicating a correlation with treatment response. Evidence Type: Oncogenic | Mutation: R132H | Summary: The R132H variant contributes to tumor development or progression, as it is implicated in cancer-related pathways.
Gene→Variant (gene-first): 3417:R132H
Genes: 3417
Variants: R132H
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
[Paper-level Aggregated] PMCID: PMC8203843
Evidence Type(s): Oncogenic, Predictive
Justification: Oncogenic: The IDH1 R132H mutation is associated with glioma and is known to induce homologous recombination defects, which contributes to the oncogenic process in these tumors. Predictive: The study demonstrates that the presence of the IDH1 R132H mutation influences sensitivity to PARP inhibitors, indicating that this variant can predict treatment response in glioma patients.
Gene→Variant (gene-first): IDH1(3417):R132H
Genes: IDH1(3417)
Variants: R132H
As described earlier, ATRX and IDH1/2 mutations co-occur frequently in glioma, and we and others have reported that the latter induce HR defects and PARP inhibitor sensitivity. We thus wanted to understand how PARPi sens
[Paragraph-level] PMCID: PMC8203843 Section: RESULTS PassageIndex: 11
Evidence Type(s): Predictive, Oncogenic
Justification: Predictive: The passage discusses how IDH1 mutations, specifically R132H, induce sensitivity to PARP inhibitors, indicating a correlation with treatment response. Oncogenic: The context implies that the IDH1 R132H mutation contributes to tumor behavior, particularly in the context of glioma and its interaction with ATRX mutations.
Gene→Variant (gene-first): 3417:R132H
Genes: 3417
Variants: R132H
IDH1 R132H and ATRX KO have similar levels of PARP inhibitor sensitivity.
[Paragraph-level] PMCID: PMC8203843 Section: ABSTRACT PassageIndex: 4
Evidence Type(s): Predictive
Justification: Predictive: The passage indicates that IDH1 R132H is associated with sensitivity to PARP inhibitors, which correlates the variant with a specific therapy response.
Gene→Variant (gene-first): 3417:R132H
Genes: 3417
Variants: R132H
IDH1 R132H and ATRX KO have similar levels of PARP inhibitor sensitivity.
[Paragraph-level] PMCID: PMC8203843 Section: ABSTRACT PassageIndex: 4
Evidence Type(s): Predictive
Justification: Predictive: The passage indicates that IDH1 R132H is associated with sensitivity to PARP inhibitors, which correlates the variant with a specific therapy response.
Gene→Variant (gene-first): 3417:R132H
Genes: 3417
Variants: R132H